Dr. Onur Baser, CEO of STATinMED Research, was selected as a distance learning professor by the International Society of Pharmaceutical Outcomes Research (ISPOR). He will be teaching a course on estimation of health care costs.
Read more →Dr. Onur Baser, CEO of STATinMED Research, was selected for the Scientific Review Committee of the U.S. Institute of Education Sciences (IES), Statistics and Modeling Panel.
Read more →The President & CEO of STATinMED Research was selected for the advisory board of the Advances in Therapy journal.
Read more →STATinMED Research has two new recently accepted journal articles; one on September 29, 2011 to Thrombosis (therapeutic area: cardiovascular diseases) and one October 13, 2011 to Current Medical Research and Opinion (therapeutic area: oncology).
Read more →Grant request to the National Institute of Health STATinMED Research and The University of Michigan have jointly submitted a grant request to the National Institute of Health (NIH) related to biologics therapies for rheumatoid arthritis and their effects on elective surgeries.
Read more →Findings from O. Baser and co-researchers advance knowledge in asthma In this recent report published in the journal Value in Health, researchers in the United States conducted a study “To review the efficacy of instrumental variable (IV) models in addressing a variety of assumption violations to ensure
Read more →Metabolic screening after ADA’s consensus statement on atypical antipsychotic drugs According to the American Diabetes Association (ADA), metabolic monitoring guidelines for antipsychotics are largely unheeded. Researchers found that recommendations for lipid and glucose monitoring for patients on atypical antipsychotic drugs have made scarcely a dent on clinical
Read more →Study tracks impact of increased out-of-pocket cost from cholesterol medication A Thomson Medstat study has found that increased prescription drug co-pays are linked to lower medication usage and higher hospitalization rates. As patients face higher out-of-pocket costs for cholesterol-lowering drugs, they are less likely to take their
Read more →How careful are we when estimating treatment effect? Randomized control trials (RCT), the ideal evaluation technique for estimating treatment effects, are not always feasible or permissible, a recent study suggests. Observational studies would often be the design of choice if the investigator could adjust for the large
Read more →